| Effects of 6 months of treatment with donepezil and rivastigmine on results of neuropsychological tests of MMSE, NPI, Clock and Bender in patients with Alzheimer's disease
|
Abolfazli, R;Ghazanshahi, S;Nazeman, M
|
2008
|
| An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting
|
Aguglia, E.;Onor, M. L.;Saina, M.;Maso, E.
|
2004
|
| High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial
|
Aisen, P. S.;Schneider, L. S.;Sano, M.;Diaz-Arrastia, R.;van Dyck, C. H.;Weiner, M. F.;Bottiglieri, T.;Jin, S.;Stokes, K. T.;Thomas, R. G.;Thal, L. J.;Alzheimer Disease Cooperative, Study
|
2008
|
| Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease
|
Alva, G.;Cummings, J. L.;Galvin, J. E.;Meng, X.;Velting, D. M.
|
2015
|
| Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses
|
Alva, G.;Grossberg, G. T.;Schmitt, F. A.;Meng, X.;Olin, J. T.
|
2011
|
| Efficacy of higher-dose 13.3mg/24 h (15cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis
|
Alva, G.;Isaacson, R.;Sadowsky, C.;Grossberg, G.;Meng, X.;Somogyi, M.
|
2014
|
| The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design
|
Andersen, F.;Viitanen, M.;Halvorsen, D. S.;Straume, B.;Wilsgaard, T.;Engstad, T. A.
|
2012
|
| The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area
|
Araki, T.;Wake, R.;Miyaoka, T.;Kawakami, K.;Nagahama, M.;Furuya, M.;Limoa, E.;Liaury, K.;Hashioka, S.;Murotani, K.;Horiguchi, J.
|
2014
|
| MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia
|
Ashford, J. W.;Adamson, M.;Beale, T.;La, D.;Hernandez, B.;Noda, A.;Rosen, A.;O'Hara, R.;Fairchild, J. K.;Spielman, D.;Yesavage, J. A.
|
2011
|
| Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis
|
Atri, A.;Hendrix, S. B.;Pejovic, V.;Hofbauer, R. K.;Edwards, J.;Molinuevo, J. L.;Graham, S. M.
|
2015
|
| Caregiver distress related to neuropsychiatric symptoms is reduced with extended-release memantine cholinesterase inhibitor combination in patients with moderate to severe Alzheimer's disease
|
Atri, A;Hendrix, S;Ellison, N;Otcheretko, V;Edwards, J
|
2016
|
| Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy
|
Atri, A.;Molinuevo, J. L.;Lemming, O.;Wirth, Y.;Pulte, I.;Wilkinson, D.
|
2013
|
| Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.[Republished in J Alzheimers Dis. 2008 Feb;13(1):97-107; PMID: 18334761]
|
Bakchine, S.;Loft, H.
|
2007
|
| Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.[Republished from J Alzheimers Dis. 2007 Jul;11(4):471-9; PMID: 17656827]
|
Bakchine, S.;Loft, H.
|
2008
|
| Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial
|
Ballard, C.;Margallo-Lana, M.;Juszczak, E.;Douglas, S.;Swann, A.;Thomas, A.;O'Brien, J.;Everratt, A.;Sadler, S.;Maddison, C.;Lee, L.;Bannister, C.;Elvish, R.;Jacoby, R.
|
2005
|
| A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD)
|
Ballard, C.;Thomas, A.;Gerry, S.;Yu, L. M.;Aarsland, D.;Merritt, C.;Corbett, A.;Davison, C.;Sharma, N.;Khan, Z.;Creese, B.;Loughlin, P.;Bannister, C.;Burns, A.;Win, S. N.;Walker, Z.;Main-Ad investigators
|
2015
|
| Impact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's disease
|
Belitskaya-Levy, I.;Dysken, M.;Guarino, P.;Sano, M.;Asthana, S.;Vertrees, J. E.;Pallaki, M.;Llorente, M.;Love, S.;Schellenberg, G.
|
2018
|
| Rivastigmine for Alzheimer's disease
|
Birks, J. S.;Chong, L. Y.;Grimley Evans, J.
|
|
| Donepezil for dementia due to Alzheimer's disease. [Review][Update of Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001190; PMID: 16437430]
|
Birks, J. S.;Harvey, R. J.
|
2018
|
| Donepezil preserves cognition and global function in patients with severe Alzheimer disease
|
Black, S. E.;Doody, R.;Li, H.;McRae, T.;Jambor, K. M.;Xu, Y.;Sun, Y.;Perdomo, C. A.;Richardson, S.
|
2007
|
| Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease
|
Brodaty, H.;Corey-Bloom, J.;Potocnik, F. C.;Truyen, L.;Gold, M.;Damaraju, C. R.
|
2005
|
| Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease
|
Bullock, R.;Bergman, H.;Touchon, J.;Gambina, G.;He, Y.;Nagel, J.;Lane, R.
|
2006
|
| Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period
|
Bullock, R.;Touchon, J.;Bergman, H.;Gambina, G.;He, Y.;Rapatz, G.;Nagel, J.;Lane, R.
|
2005
|
| Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial
|
Burns, A.;Bernabei, R.;Bullock, R.;Cruz Jentoft, A. J.;Frolich, L.;Hock, C.;Raivio, M.;Triau, E.;Vandewoude, M.;Wimo, A.;Came, E.;Van Baelen, B.;Hammond, G. L.;van Oene, J. C.;Schwalen, S.
|
2009
|
| The effects of donepezil in Alzheimer's disease - results from a multinational trial
|
Burns, A.;Rossor, M.;Hecker, J.;Gauthier, S.;Petit, H.;Moller, H. J.;Rogers, S. L.;Friedhoff, L. T.
|
1999
|
| Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease
|
Burns, A.;Spiegel, R.;Quarg, P.
|
2004
|
| Effect of cold pressed coconut oil on cognition and behavior among patients with Alzheimer's disease - A pilot intervention study
|
Chan, S. C.;Esther, G. E.;Yip, H. L.;Sugathan, S.;Chin, P. S.
|
2017
|
| A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients
|
Chan, W. C.;Lam, L. C.;Choy, C. N.;Leung, V. P.;Li, S. W.;Chiu, H. F.
|
2001
|
| Clinical study on the treatment of Alzheimer's disease by traditional Chinese and western medicine
|
Chen, W;Liang, Jf;Jiang, Lf;Wu, L;Hu, Yq;He, Qc
|
2015
|
| A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease
|
Connelly, P. J.;Prentice, N. P.;Cousland, G.;Bonham, J.
|
2008
|
| A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
|
Corey-Bloom, J.;Anand, R.;Veach, J.
|
1998
|
| Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants
|
Cornelli, U.
|
2010
|
| Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations
|
Cummings, J.;Emre, M.;Aarsland, D.;Tekin, S.;Dronamraju, N.;Lane, R.
|
2010
|
| Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer's disease
|
Cummings, J.;Froelich, L.;Black, S. E.;Bakchine, S.;Bellelli, G.;Molinuevo, J. L.;Kressig, R. W.;Downs, P.;Caputo, A.;Strohmaier, C.
|
2012
|
| Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis
|
Cummings, J.;Jones, R.;Wilkinson, D.;Lopez, O.;Gauthier, S.;Waldemar, G.;Zhang, R.;Xu, Y.;Sun, Y.;Richardson, S.;Mackell, J.
|
2010
|
| Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis
|
Cummings, J. L.;Ferris, S. H.;Farlow, M. R.;Olin, J. T.;Meng, X.
|
2010
|
| Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease
|
Cummings, J. L.;Farlow, M. R.;Meng, X.;Tekin, S.;Olin, J. T.
|
2010
|
| Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial
|
De Jesus Moreno Moreno, M.
|
2003
|
| Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study
|
Demarin, V.;Podobnik, S. S.;Storga-Tomic, D.;Kay, G.
|
2004
|
| Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease
|
Doody, R. S.;Corey-Bloom, J.;Zhang, R.;Li, H.;Ieni, J.;Schindler, R.
|
2008
|
| Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease
|
Doody, R. S.;Dunn, J. K.;Clark, C. M.;Farlow, M.;Foster, N. L.;Liao, T.;Gonzales, N.;Lai, E.;Massman, P.
|
2001
|
| Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
|
Doody, R. S.;Geldmacher, D. S.;Gordon, B.;Perdomo, C. A.;Pratt, R. D.;Donepezil Study, Group
|
2001
|
| Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine
|
Doody, R. S.;Geldmacher, D. S.;Farlow, M. R.;Sun, Y.;Moline, M.;Mackell, J.
|
2012
|
| Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study
|
Dunbar, F.;Zhu, Y.;Brashear, H. R.
|
2006
|
| Ondansetron in the treatment of cognitive decline in Alzheimer dementia
|
Dysken, M.;Kuskowski, M.;Love, S.;Ondansetron Study, Group
|
2002
|
| Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease
|
Emre, M.;Mecocci, P.;Stender, K.
|
2008
|
| Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study
|
Eriksdotter, M.;Vedin, I.;Falahati, F.;Freund-Levi, Y.;Hjorth, E.;Faxen-Irving, G.;Wahlund, L. O.;Schultzberg, M.;Basun, H.;Cederholm, T.;Palmblad, J.
|
2015
|
| Rivastigmine in patients with Alzheimer's disease and concurrent hypertension
|
Erkinjuntti, T.;Skoog, I.;Lane, R.;Andrews, C.
|
2002
|
| Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease
|
Farlow, M. R.;Cummings, J. L.;Olin, J. T.;Meng, X.
|
2010
|
| The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease
|
Farlow, M. R.;Doraiswamy, P. M.;Meng, X.;Cooke, K.;Somogyi, M.
|
2011
|
| Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials
|
Farlow, M. R.;Graham, S. M.;Alva, G.
|
2008
|
| Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy
|
Farlow, M. R.;Grossberg, G. T.;Meng, X.;Olin, J.;Somogyi, M.
|
2011
|
| A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia
|
Farlow, M. R.;Grossberg, G. T.;Sadowsky, C. H.;Meng, X.;Somogyi, M.
|
2013
|
| Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease
|
Farlow, Martin R.;Sadowsky, C. H.;Velting, D. M.;Meng, X.;Islam, M. Z.
|
2015
|
| Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
|
Farlow, M.;Veloso, F.;Moline, M.;Yardley, J.;Brand-Schieber, E.;Bibbiani, F.;Zou, H.;Hsu, T.;Satlin, A.
|
2011
|
| Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial
|
Farokhnia, M.;Shafiee Sabet, M.;Iranpour, N.;Gougol, A.;Yekehtaz, H.;Alimardani, R.;Farsad, F.;Kamalipour, M.;Akhondzadeh, S.
|
2014
|
| A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.[Erratum appears in Neurology 2001 Dec 11;57(11):2153]
|
Feldman, H.;Gauthier, S.;Hecker, J.;Vellas, B.;Subbiah, P.;Whalen, E.;Donepezil, Msad Study Investigators Group
|
2001
|
| Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.[Erratum appears in J Am Geriatr Soc. 2003 Sep;51(9):1331]
|
Feldman, H.;Gauthier, S.;Hecker, J.;Vellas, B.;Emir, B.;Mastey, V.;Subbiah, P.;Donepezil, Msad Study Investigators Group
|
2003
|
| Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial
|
Feldman, H.;Gauthier, S.;Hecker, J.;Vellas, B.;Xu, Y.;Ieni, J. R.;Schwam, E. M.;Donepezil, Msad Study Investigators Group
|
2005
|
| Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease
|
Feldman, H. H.;Lane, R.;Study, Group
|
2007
|
| Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment
|
Feldman, H. H.;Schmitt, F. A.;Olin, J. T.;Memantine, M. E. M. M. D. Study Group
|
2006
|
| Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
|
Ferris, S.;Cummings, J.;Christensen, D.;Doody, R.;Farlow, M.;Sabbagh, M.;Liu, L.;Mackell, J.;Fain, R.
|
2013
|
| Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
|
Ferris, S. H.;Schmitt, F. A.;Saxton, J.;Richardson, S.;Mackell, J.;Sun, Y.;Xu, Y.
|
2011
|
| Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients
|
Ferris, S.;Ihl, R.;Robert, P.;Winblad, B.;Gatz, G.;Tennigkeit, F.;Gauthier, S.
|
2009
|
| Cognitive efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch in severe Alzheimer's disease: severe impairment battery factor analysis
|
Ferris, S;Isaacson, R;Velting, D;Meng, X
|
2014
|
| Rivastigmine in moderately severe-to-severe Alzheimer's disease: Severe Impairment Battery factor analysis
|
Ferris, S.;Karantzoulis, S.;Somogyi, M.;Meng, X.
|
2013
|
| Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: Findings from a randomized controlled trial
|
Fields, Cynthia;Drye, Lea;Vaidya, Vijay;Lyketsos, Constantine
|
2012
|
| Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial
|
Freund-Levi, Y.;Eriksdotter-Jonhagen, M.;Cederholm, T.;Basun, H.;Faxen-Irving, G.;Garlind, A.;Vedin, I.;Vessby, B.;Wahlund, L. O.;Palmblad, J.
|
2006
|
| Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease
|
Gauthier, S.;Feldman, H.;Hecker, J.;Vellas, B.;Emir, B.;Subbiah, P.;Donepezil, Msad Study Investigators' Group
|
2002
|
| Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease
|
Gleason, C. E.;Fischer, B. L.;Dowling, N. M.;Setchell, K. D.;Atwood, C. S.;Carlsson, C. M.;Asthana, S.
|
2015
|
| Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease
|
Grossberg, G.;Cummings, J.;Frolich, L.;Bellelli, G.;Molinuevo, J. L.;Krahnke, T.;Strohmaier, C.
|
2013
|
| Rivastigmine in Alzheimer disease: efficacy over two years.[Erratum appears in Am J Geriatr Psychiatry. 2004 Nov-Dec;12(6):679]
|
Grossberg, G.;Irwin, P.;Satlin, A.;Mesenbrink, P.;Spiegel, R.
|
2004
|
| Effects of transdermal rivastigmine on ADAS-Cog items in mild-to-moderate Alzheimer's disease
|
Grossberg, Gt;Schmitt, Fa;Xiangyi, Meng;Tekin, S;Olin, J
|
2010
|
| Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors
|
Grossberg, G. T.;Alva, G.;Hendrix, S.;Ellison, N.;Kane, M. C.;Edwards, J.
|
2018
|
| Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor
|
Grossberg, G. T.;Farlow, M. R.;Meng, X.;Velting, D. M.
|
2015
|
| The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors
|
Grossberg, G. T.;Manes, F.;Allegri, R. F.;Gutierrez-Robledo, L. M.;Gloger, S.;Xie, L.;Jia, X. D.;Pejovic, V.;Miller, M. L.;Perhach, J. L.;Graham, S. M.
|
2013
|
| Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease
|
Grossberg, G. T.;Olin, J. T.;Somogyi, M.;Meng, X.
|
2011
|
| Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications
|
Grossberg, G. T.;Stahelin, H. B.;Messina, J. C.;Anand, R.;Veach, J.
|
2000
|
| Reviews: Effects of transdermal rivastigmine on ADAS-Cog items in mild-to-moderate Alzheimer's disease
|
Grossberg, George T.;Schmitt, Frederick A.;Meng, Xiangyi;Tekin, Sibel;Olin, Jason
|
2010
|
| Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease.[Erratum appears in Neuropsychiatr Dis Treat. 2014;10:1997]
|
Hager, K.;Baseman, A. S.;Nye, J. S.;Brashear, H. R.;Han, J.;Sano, M.;Davis, B.;Richards, H. M.
|
2014
|
| Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study
|
Hager, K.;Baseman, A. S.;Nye, J. S.;Brashear, H. R.;Han, J.;Sano, M.;Davis, B.;Richards, H. M.
|
2016
|
| Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients
|
Han, H. J.;Kim, B. C.;Lee, J. Y.;Ryu, S. H.;Na, H. R.;Yoon, S. J.;Park, H. Y.;Shin, J. H.;Cho, S. J.;Yi, H. A.;Choi, M. S.;Heo, J. H.;Park, K. W.;Kim, K. K.;Choi, S. H.
|
2012
|
| Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease
|
Han, S. H.;Lee, J. H.;Kim, S. Y.;Park, K. W.;Chen, C.;Tripathi, M.;Dash, A.;Kubota, N.
|
2017
|
| Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD
|
Hellweg, R.;Wirth, Y.;Janetzky, W.;Hartmann, S.
|
2012
|
| Improvement of cognitive deficit in Alzheimer's disease patients by long term treatment with korean red ginseng
|
Heo, J. H.;Lee, S. T.;Oh, M. J.;Park, H. J.;Shim, J. Y.;Chu, K.;Kim, M.
|
2011
|
| Heat-processed ginseng enhances the cognitive function in patients with moderately severe Alzheimer's disease
|
Heo, J. H.;Lee, S. T.;Chu, K.;Oh, M. J.;Park, H. J.;Shim, J. Y.;Kim, M.
|
2012
|
| Effects of combined pharmacologic and cognitive treatment in the progression of moderate dementia: a two-year follow-up
|
Hernandez, Cr;Unturbe, Fm;Martinez-Lage, Pc;Lucas, Af;Gregorio, Pg;Ortiz, Alonso T
|
2007
|
| A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease
|
Herrmann, N.;Gauthier, S.;Boneva, N.;Lemming, O. M.;Investigators
|
2013
|
| Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease
|
Heyman, A.;Schmechel, D.;Wilkinson, W.;Rogers, H.;Krishnan, R.;Holloway, D.;Schultz, K.;Gwyther, L.;Peoples, R.;Utley, C.;et al.,
|
1987
|
| Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial
|
Homma, A.;Atarashi, H.;Kubota, N.;Nakai, K.;Takase, T.
|
2016
|
| Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial
|
Homma, A.;Imai, Y.;Tago, H.;Asada, T.;Shigeta, M.;Iwamoto, T.;Takita, M.;Arimoto, I.;Koma, H.;Ohbayashi, T.
|
2008
|
| Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group
|
Homma, A.;Takeda, M.;Imai, Y.;Udaka, F.;Hasegawa, K.;Kameyama, M.;Nishimura, T.
|
2000
|
| Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761 in Alzheimer's disease and vascular dementia: results from a randomised controlled trial
|
Ihl, R.;Tribanek, M.;Bachinskaya, N.;Gotaday Study Group
|
2012
|
| Bromocriptine treatment for perseveration in demented patients
|
Imamura, T.;Takanashi, M.;Hattori, N.;Fujimori, M.;Yamashita, H.;Ishii, K.;Yamadori, A.
|
1998
|
| Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease
|
Isaacson, R. S.;Ferris, S.;Velting, D. M.;Meng, X.
|
2016
|
| Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial
|
Jia, J.;Wei, C.;Jia, L.;Tang, Y.;Liang, J.;Zhou, A.;Li, F.;Shi, L.;Doody, R. S.
|
2017
|
| Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial
|
Kamphuis, P. J.;Verhey, F. R.;Olde Rikkert, M. G.;Twisk, J. W.;Swinkels, S. H.;Scheltens, P.
|
2011
|
| Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer's disease: secondary analyses from a randomized, controlled trial
|
Kamphuis, P. J.;Verhey, F. R.;Olde Rikkert, M. G.;Twisk, J. W.;Swinkels, S. H.;Scheltens, P.
|
2011
|
| Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer's disease receiving donepezil
|
Kano, O;Ito, H;Takazawa, T;Kawase, Y;Murata, K;Iwamoto, K;Nagaoka, T;Hirayama, T;Miura, K;Nagata, R;Kiyozuka, T;Aoyagi, J;Sato, R;Eguchi, T;Ikeda, K;Iwasaki, Y
|
2013
|
| Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia
|
Kanowski, S.;Herrmann, W. M.;Stephan, K.;Wierich, W.;Horr, R.
|
1996
|
| Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial
|
Kanowski, S.;Hoerr, R.
|
2003
|
| A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease
|
Karaman, Y.;Erdogan, F.;Koseoglu, E.;Turan, T.;Ersoy, A. O.
|
2005
|
| Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial
|
Kessler, H.;Bayer, T. A.;Bach, D.;Schneider-Axmann, T.;Supprian, T.;Herrmann, W.;Haber, M.;Multhaup, G.;Falkai, P.;Pajonk, F. G.
|
2008
|
| Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease
|
Krishnan, K. R.;Charles, H. C.;Doraiswamy, P. M.;Mintzer, J.;Weisler, R.;Yu, X.;Perdomo, C.;Ieni, J. R.;Rogers, S.
|
2003
|
| Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation
|
Kudoh, C;Arita, R;Honda, M;Kishi, T;Komatsu, Y;Asou, H
|
2016
|
| An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors
|
Kumar, V.;Anand, R.;Messina, J.;Hartman, R.;Veach, J.
|
2000
|
| Disease stage in Alzheimer disease and treatment effects of rivastigmine
|
Kurz, A.;Farlow, M.;Quarg, P.;Spiegel, R.
|
2004
|
| A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people
|
Kwok, T.;Lee, J.;Law, C. B.;Pan, P. C.;Yung, C. Y.;Choi, K. C.;Lam, L. C.
|
2011
|
| Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: results from a short-term, randomized, double-blind trial
|
Kyomen, H. H.;Satlin, A.;Hennen, J.;Wei, J. Y.
|
1999
|
| A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group
|
Le Bars, P. L.;Katz, M. M.;Berman, N.;Itil, T. M.;Freedman, A. M.;Schatzberg, A. F.
|
1997
|
| A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia
|
Le Bars, P. L.;Kieser, M.;Itil, K. Z.
|
2000
|
| Influence of the severity of cognitive impairment on the effect of the Gnkgo biloba extract EGb 761 in Alzheimer's disease
|
Le Bars, P. L.;Velasco, F. M.;Ferguson, J. M.;Dessain, E. C.;Kieser, M.;Hoerr, R.
|
2002
|
| Panax ginseng enhances cognitive performance in Alzheimer disease
|
Lee, S. T.;Chu, K.;Sim, J. Y.;Heo, J. H.;Kim, M.
|
2008
|
| Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study
|
Leszek, J.;Inglot, A. D.;Janusz, M.;Lisowski, J.;Krukowska, K.;Georgiades, J. A.
|
1999
|
| A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease
|
Little, A.;Levy, R.;Chuaqui-Kidd, P.;Hand, D.
|
1985
|
| Acetyl-l-carnitine in dementia
|
Livingston, G. A.;Sax, K. B.;McClenahan, Z.;Blumenthal, E.;Foley, K.;Willison, J.;Mann, A. H.;James, I. M.
|
1991
|
| Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental
|
Lloret, A.;Badia, M. C.;Mora, N. J.;Pallardo, F. V.;Alonso, M. D.;Vina, J.
|
2009
|
| Effect of memantine on resting state default mode network activity in Alzheimer's disease
|
Lorenzi, M.;Beltramello, A.;Mercuri, N. B.;Canu, E.;Zoccatelli, G.;Pizzini, F. B.;Alessandrini, F.;Cotelli, M.;Rosini, S.;Costardi, D.;Caltagirone, C.;Frisoni, G. B.
|
2011
|
| SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
|
Maher-Edwards, G.;Dixon, R.;Hunter, J.;Gold, M.;Hopton, G.;Jacobs, G.;Hunter, J.;Williams, P.
|
2011
|
| Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease
|
Maher-Edwards, G.;Watson, C.;Ascher, J.;Barnett, C.;Boswell, D.;Davies, J.;Fernandez, M.;Kurz, A.;Zanetti, O.;Safirstein, B.;Schronen, J. P.;Zvartau-Hind, M.;Gold, M.
|
2015
|
| A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease
|
Malpas, C. B.;Vivash, L.;Genc, S.;Saling, M. M.;Desmond, P.;Steward, C.;Hicks, R. J.;Callahan, J.;Brodtmann, A.;Collins, S.;Macfarlane, S.;Corcoran, N. M.;Hovens, C. M.;Velakoulis, D.;O'Brien, T. J.
|
2016
|
| Opioid treatment for agitation in patients with advanced dementia
|
Manfredi, P. L.;Breuer, B.;Wallenstein, S.;Stegmann, M.;Bottomley, G.;Libow, L.
|
2003
|
| Effects of a MAO-B inhibitor in the treatment of Alzheimer disease
|
Mangoni, A.;Grassi, M.;Frattola, Lodovico;Piolti, R.;Bassi, S.;Motta, A.;Marcone, A.;Smirne, S.
|
1991
|
| Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study
|
Mazza, M.;Capuano, A.;Bria, P.;Mazza, S.
|
2006
|
| Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial
|
McCarney, R.;Fisher, P.;Iliffe, S.;van Haselen, R.;Griffin, M.;van der Meulen, J.;Warner, J.
|
2008
|
| Preliminary findings of high-dose thiamine in dementia of Alzheimer's type
|
Meador, K.;Loring, D.;Nichols, M.;Zamrini, E.;Rivner, M.;Posas, H.;Thompson, E.;Moore, E.
|
1993
|
| Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies
|
Mecocci, P.;Bladstrom, A.;Stender, K.
|
2009
|
| Efficacy of 13.3mg/24h versus 4.6mg/24h rivastigmine patch on activities of daily living in severe Alzheimer's disease
|
Micca, J. L.;Galvin, J. E.;Velting, D. M.;Meng, X.
|
2014
|
| Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy
|
Modrego, P. J.;Fayed, N.;Errea, J. M.;Rios, C.;Pina, M. A.;Sarasa, M.
|
2010
|
| A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.[Erratum appears in Neurology 2001 Nov 27;57(10):1942]
|
Mohs, R. C.;Doody, R. S.;Morris, J. C.;Ieni, J. R.;Rogers, S. L.;Perdomo, C. A.;Pratt, R. D.;Study, Group
|
2001
|
| Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch
|
Molinuevo, J. L.;Frolich, L.;Grossberg, G. T.;Galvin, J. E.;Cummings, J. L.;Krahnke, T.;Strohmaier, C.
|
2015
|
| The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study
|
Moraes Wdos, S.;Poyares, D. R.;Guilleminault, C.;Ramos, L. R.;Bertolucci, P. H.;Tufik, S.
|
2006
|
| Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer's disease
|
Moretti, D. V.
|
2014
|
| Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease
|
Moretti, D. V.;Frisoni, G. B.;Binetti, G.;Zanetti, O.
|
2014
|
| A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease
|
Nakamura, Y.;Imai, Y.;Shigeta, M.;Graf, A.;Shirahase, T.;Kim, H.;Fujii, A.;Mori, J.;Homma, A.
|
2011
|
| Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan
|
Nakamura, Y.;Kitamura, S.;Homma, A.;Shiosakai, K.;Matsui, D.
|
2014
|
| Supplementary Material for: a 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease
|
Nakamura, Y;Strohmaier, C;Tamura, K;Kataoka, N;Nakano, M;Oda, S;Nishimura, K;Homma, A
|
2015
|
| A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease
|
Nakamura, Y.;Strohmaier, C.;Tamura, K.;Kataoka, N.;Nakano, M.;Oda, S.;Nishimura, K.;Homma, A.
|
2015
|
| Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia
|
Nasab, N. M.;Bahrammi, M. A.;Nikpour, M. R.;Rahim, F.;Naghibis, S. N.
|
2012
|
| A trial of thiamine in Alzheimer's disease
|
Nolan, K. A.;Black, R. S.;Sheu, K. F.;Langberg, J.;Blass, J. P.
|
1991
|
| Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study
|
Olde Rikkert, M. G.;Verhey, F. R.;Blesa, R.;von Arnim, C. A.;Bongers, A.;Harrison, J.;Sijben, J.;Scarpini, E.;Vandewoude, M. F.;Vellas, B.;Witkamp, R.;Kamphuis, P. J.;Scheltens, P.
|
2015
|
| Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease
|
Onofrj, M.;Thomas, A.;Luciano, A. L.;Iacono, D.;Di Rollo, A.;D'Andreamatteo, G.;Di Iorio, A.
|
2002
|
| Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease
|
Ott, B. R.;Blake, L. M.;Kagan, E.;Resnick, M.;Memantine, M. E. M. M. D. A. B. Study Group
|
2007
|
| Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial
|
Peskind, E. R.;Potkin, S. G.;Pomara, N.;Ott, B. R.;Graham, S. M.;Olin, J. T.;McDonald, S.
|
2006
|
| Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naive patients with mild-to-moderate Alzheimer's disease
|
Peters, O.;Fuentes, M.;Joachim, L. K.;Jessen, F.;Luckhaus, C.;Kornhuber, J.;Pantel, J.;Hull, M.;Schmidtke, K.;Ruther, E.;Moller, H. J.;Kurz, A.;Wiltfang, J.;Maier, W.;Wiese, B.;Frolich, L.;Heuser, I.
|
2015
|
| Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial
|
Pomara, N.;Ott, B. R.;Peskind, E.;Resnick, E. M.
|
2007
|
| Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial
|
Porsteinsson, A. P.;Grossberg, G. T.;Mintzer, J.;Olin, J. T.;Memantine, M. E. M. M. D. Study Group
|
2008
|
| Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease
|
Potki, S. G.;Anand, R.;Hartman, R.;Veach, J.;Grossberg, G.
|
2002
|
| Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
|
Quinn, J. F.;Raman, R.;Thomas, R. G.;Yurko-Mauro, K.;Nelson, E. B.;Van Dyck, C.;Galvin, J. E.;Emond, J.;Jack, C. R., Jr.;Weiner, M.;Shinto, L.;Aisen, P. S.
|
2010
|
| Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia
|
Rai, G.;Wright, G.;Scott, L.;Beston, B.;Rest, J.;Exton-Smith, A. N.
|
1990
|
| Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group
|
Raskind, M. A.;Peskind, E. R.;Wessel, T.;Yuan, W.
|
2000
|
| Rivastigmine for Alzheimer's Disease: Improvement Versus Reduced Worsening
|
Raskind, M.;Kumar, V.;Malaty, L.;Messina, J.;Hartman, R.;Anand, R.
|
2000
|
| Memantine in moderate-to-severe Alzheimer's disease
|
Reisberg, B.;Doody, R.;Stoffler, A.;Schmitt, F.;Ferris, S.;Mobius, H. J.;Memantine Study, Group
|
2003
|
| Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study
|
Ringman, J. M.;Frautschy, S. A.;Teng, E.;Begum, A. N.;Bardens, J.;Beigi, M.;Gylys, K. H.;Badmaev, V.;Heath, D. D.;Apostolova, L. G.;Porter, V.;Vanek, Z.;Marshall, G. A.;Hellemann, G.;Sugar, C.;Masterman, D. L.;Montine, T. J.;Cummings, J. L.;Cole, G. M.
|
2012
|
| Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease
|
Risner, M. E.;Saunders, A. M.;Altman, J. F.;Ormandy, G. C.;Craft, S.;Foley, I. M.;Zvartau-Hind, M. E.;Hosford, D. A.;Roses, A. D.;Rosiglitazone in Alzheimer's Disease Study, Group
|
2006
|
| A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group
|
Rogers, S. L.;Farlow, M. R.;Doody, R. S.;Mohs, R.;Friedhoff, L. T.
|
1998
|
| Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.[Erratum appears in BMJ 2001 Jun 16;322(7300):1456]
|
Rosler, M.;Anand, R.;Cicin-Sain, A.;Gauthier, S.;Agid, Y.;Dal-Bianco, P.;Stahelin, H. B.;Hartman, R.;Gharabawi, M.
|
1999
|
| Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response
|
Sabbagh, M.;Cummings, J.;Christensen, D.;Doody, R.;Farlow, M.;Liu, L.;Mackell, J.;Fain, R.
|
2013
|
| Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: Data from three clinical trials
|
Sadowsky, C. H.;Farlow, M. R.;Meng, X.;Olin, J. T.
|
2010
|
| Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis
|
Sadowsky, C. H.;Grossberg, G. T.;Somogyi, M.;Meng, X.
|
2011
|
| Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease
|
Salloway, S.;Mintzer, J.;Cummings, J. L.;Geldmacher, D.;Sun, Y.;Yardley, J.;Mackell, J.
|
2012
|
| Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease
|
Sano, M.;Bell, K.;Cote, L.;Dooneief, G.;Lawton, A.;Legler, L.;Marder, K.;Naini, A.;Stern, Y.;Mayeux, R.
|
1992
|
| A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study
|
Sano, M.;Ernesto, C.;Thomas, R. G.;Klauber, M. R.;Schafer, K.;Grundman, M.;Woodbury, P.;Growdon, J.;Cotman, C. W.;Pfeiffer, E.;Schneider, L. S.;Thal, L. J.
|
1997
|
| Souvenaid improves memory in drug-naive patients with mild Alzheimer's disease: results from a randomized, controlled, double-blind study (souvenir II)
|
Scheltens, P;Twisk, J;Blesa, R;Scarpini, E;Arnim, C;Bongers, A
|
2012
|
| Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial
|
Scheltens, P.;Twisk, J. W.;Blesa, R.;Scarpini, E.;von Arnim, C. A.;Bongers, A.;Harrison, J.;Swinkels, S. H.;Stam, C. J.;de Waal, H.;Wurtman, R. J.;Wieggers, R. L.;Vellas, B.;Kamphuis, P. J.
|
2012
|
| Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis
|
Schmitt, F. A.;van Dyck, C. H.;Wichems, C. H.;Olin, J. T.;Memantine, M. E. M. M. D. Study Group
|
2006
|
| A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type
|
Schneider, L. S.;DeKosky, S. T.;Farlow, M. R.;Tariot, P. N.;Hoerr, R.;Kieser, M.
|
2005
|
| Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.[Erratum appears in Arch Neurol. 2005 May;62(5):825]
|
Seltzer, B.;Zolnouni, P.;Nunez, M.;Goldman, R.;Kumar, D.;Ieni, J.;Richardson, S.;Donepezil "402" Study, Group
|
2004
|
| The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease
|
Shah, R. C.;Kamphuis, P. J.;Leurgans, S.;Swinkels, S. H.;Sadowsky, C. H.;Bongers, A.;Rappaport, S. A.;Quinn, J. F.;Wieggers, R. L.;Scheltens, P.;Bennett, D. A.
|
2013
|
| Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease
|
Shao, Z. Q.
|
2015
|
| Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial
|
Shimizu, S.;Kanetaka, H.;Hirose, D.;Sakurai, H.;Hanyu, H.
|
2015
|
| A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease
|
Shinto, L.;Quinn, J.;Montine, T.;Dodge, H. H.;Woodward, W.;Baldauf-Wagner, S.;Waichunas, D.;Bumgarner, L.;Bourdette, D.;Silbert, L.;Kaye, J.
|
2014
|
| Long-term acetyl-L-carnitine treatment in Alzheimer's disease
|
Spagnoli, A.;Lucca, U.;Menasce, G.;Bandera, L.;Cizza, G.;Forloni, G.;Tettamanti, M.;Frattura, L.;Tiraboschi, P.;Comelli, M.;et al.,
|
1991
|
| An open-label, multicenter observational study for patients with Alzheimer's disease treated with memantine in the clinical practice
|
Stamouli, S. S.;Tzanakaki, M.;Giatas, S.;Georgiadis, G.;Papalexi, E.;Parashos, I. A.
|
2011
|
| Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: a 52-week prospective study
|
Suh, G. H.;Jung, H. Y.;Lee, C. U.;Choi, S.;Korean Galantamine Study, Group
|
2008
|
| Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial
|
Sultzer, D. L.;Davis, S. M.;Tariot, P. N.;Dagerman, K. S.;Lebowitz, B. D.;Lyketsos, C. G.;Rosenheck, R. A.;Hsiao, J. K.;Lieberman, J. A.;Schneider, L. S.;Catie-Ad Study Group
|
2008
|
| Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients
|
Sun, Y.;Lu, C. J.;Chien, K. L.;Chen, S. T.;Chen, R. C.
|
2007
|
| A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting
|
Tariot, P. N.;Cummings, J. L.;Katz, I. R.;Mintzer, J.;Perdomo, C. A.;Schwam, E. M.;Whalen, E.
|
2001
|
| Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial
|
Tariot, P. N.;Farlow, M. R.;Grossberg, G. T.;Graham, S. M.;McDonald, S.;Gergel, I.;Memantine Study, Group
|
2004
|
| Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease
|
Tariot, P.;Salloway, S.;Yardley, J.;Mackell, J.;Moline, M.
|
2012
|
| A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease
|
Thal, L. J.;Carta, A.;Clarke, W. R.;Ferris, S. H.;Friedland, R. P.;Petersen, R. C.;Pettegrew, J. W.;Pfeiffer, E.;Raskind, M. A.;Sano, M.;Tuszynski, M. H.;Woolson, R. F.
|
1996
|
| Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months
|
Thomas, A.;Iacono, D.;Bonanni, L.;D'Andreamatteo, G.;Onofrj, M.
|
2001
|
| Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study
|
Tune, L.;Tiseo, P. J.;Ieni, J.;Perdomo, C.;Pratt, R. D.;Votaw, J. R.;Jewart, R. D.;Hoffman, J. M.
|
2003
|
| A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
|
Turner, R. S.;Thomas, R. G.;Craft, S.;van Dyck, C. H.;Mintzer, J.;Reynolds, B. A.;Brewer, J. B.;Rissman, R. A.;Raman, R.;Aisen, P. S.;Alzheimer's Disease Cooperative, Study
|
2015
|
| Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia
|
Viscogliosi, G.;Chiriac, I. M.;Ettorre, E.
|
2017
|
| Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial
|
Wade, A. G.;Farmer, M.;Harari, G.;Fund, N.;Laudon, M.;Nir, T.;Frydman-Marom, A.;Zisapel, N.
|
2014
|
| Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial
|
Wang, T.;Huang, Q.;Reiman, E. M.;Chen, K.;Li, X.;Li, G.;Lin, Z.;Li, C.;Xiao, S.
|
2013
|
| A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease
|
Wilcock, G.;Howe, I.;Coles, H.;Lilienfeld, S.;Truyen, L.;Zhu, Y.;Bullock, R.;Kershaw, P.;Gal-Gbr- Study Group
|
2003
|
| Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies
|
Wilcock, G. K.;Ballard, C. G.;Cooper, J. A.;Loft, H.
|
2008
|
| Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.[Erratum appears in BMJ 2001 Feb 17;322(7283):405]
|
Wilcock, G. K.;Lilienfeld, S.;Gaens, E.
|
2000
|
| Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease
|
Wilkinson, D.;Andersen, H. F.
|
2007
|
| Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial
|
Wilkinson, D.;Fox, N. C.;Barkhof, F.;Phul, R.;Lemming, O.;Scheltens, P.
|
2012
|
| Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease
|
Wilkinson, D.;Schindler, R.;Schwam, E.;Waldemar, G.;Jones, R. W.;Gauthier, S.;Lopez, O. L.;Cummings, J.;Xu, Y.;Feldman, H. H.
|
2009
|
| An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial.[Erratum appears in Dement Geriatr Cogn Disord. 2003;16(2):102]
|
Wimo, A.;Winblad, B.;Engedal, K.;Soininen, H.;Verhey, F.;Waldemar, G.;Wetterholm, A. L.;Mastey, V.;Haglund, A.;Zhang, R.;Miceli, R.;Chin, W.;Subbiah, P.;Donepezil Nordic Study, Group
|
2003
|
| Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials
|
Winblad, B.;Black, S. E.;Homma, A.;Schwam, E. M.;Moline, M.;Xu, Y.;Perdomo, C. A.;Swartz, J.;Albert, K.
|
2009
|
| A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule
|
Winblad, B.;Cummings, J.;Andreasen, N.;Grossberg, G.;Onofrj, M.;Sadowsky, C.;Zechner, S.;Nagel, J.;Lane, R.
|
2007
|
| A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
|
Winblad, B.;Engedal, K.;Soininen, H.;Verhey, F.;Waldemar, G.;Wimo, A.;Wetterholm, A. L.;Zhang, R.;Haglund, A.;Subbiah, P.;Donepezil Nordic Study, Group
|
2001
|
| IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease
|
Winblad, B.;Grossberg, G.;Frolich, L.;Farlow, M.;Zechner, S.;Nagel, J.;Lane, R.
|
2007
|
| Memantine benefits functional abilities in moderate to severe Alzheimer's disease
|
Winblad, B.;Gauthier, S.;Astrom, D.;Stender, K.
|
2010
|
| Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.[Erratum appears in Lancet. 2006 Nov 11;368(9548):1650], [Erratum appears in Lancet. 2006 Jun 17;367(9527):1980]
|
Winblad, B.;Kilander, L.;Eriksson, S.;Minthon, L.;Batsman, S.;Wetterholm, A. L.;Jansson-Blixt, C.;Haglund, A.;Severe Alzheimer's Disease Study, Group
|
2006
|
| 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy
|
Winblad, B.;Wimo, A.;Engedal, K.;Soininen, H.;Verhey, F.;Waldemar, G.;Wetterholm, A. L.;Haglund, A.;Zhang, R.;Schindler, R.
|
2006
|
| DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study
|
Wolkowitz, O. M.;Kramer, J. H.;Reus, V. I.;Costa, M. M.;Yaffe, K.;Walton, P.;Raskind, M.;Peskind, E.;Newhouse, P.;Sack, D.;De Souza, E.;Sadowsky, C.;Roberts, E.;D. HEA-Alzheimer's Disease Collaborative Research
|
2003
|
| Effect and Safety of Huannao Yicong Formula () on Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Double-Blinded, Donepezil-Controlled Trial
|
Yang, Y.;Liu, J. P.;Fang, J. Y.;Wang, H. C.;Wei, Y.;Cao, Y.;Liu, J. G.;Liu, L. T.;Li, H.
|
2018
|
| The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients
|
Zhang, N.;Wei, C.;Du, H.;Shi, F. D.;Cheng, Y.
|
2015
|
| Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled Trial
|
Zhang, Y.;Lin, C.;Zhang, L.;Cui, Y.;Gu, Y.;Guo, J.;Wu, D.;Li, Q.;Song, W.
|
2015
|
| Correction: Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled Trial
|
Zhang, Y.;Lin, C.;Zhang, L.;Cui, Y.;Gu, Y.;Guo, J.;Wu, D.;Li, Q.;Song, W.
|
2018
|
| Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily)
|
Zhang, Z. X.;Hong, Z.;Wang, Y. P.;He, L.;Wang, N.;Zhao, Z. X.;Zhao, G.;Shang, L.;Weisskopf, M.;Callegari, F.;Strohmaier, C.
|
2016
|
| The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old
|
Barkhof, F., Polvikoski, T. M., van Straaten, E. C., Kalaria, R. N., Sulkava, R., Aronen, H. J., Niinisto, L., Rastas, S., Oinas, M., Scheltens, P., Erkinjuntti, T.
|
2007
|
| CSF biomarkers in frontotemporal lobar degeneration with known pathology
|
Bian, H., Van Swieten, J. C., Leight, S., Massimo, L., Wood, E., Forman, M., Moore, P., de Koning, I., Clark, C. M., Rosso, S., Trojanowski, J., Lee, V. M., Grossman, M.
|
2008
|
| Tc-99m HMPAO SPECT in the differential diagnosis of the dementias with histopathologic confirmation
|
Bonte, F. J., Harris, T. S., Hynan, L. S., Bigio, E. H., White, C. L., 3rd
|
2006
|
| TC-99m HMPAO Brain Blood Flow Imaging in the Dementias with Histopathologic Correlation in 73 Patients
|
Bonte, F. J., Hynan, L., Harris, T. S., White, C. L., 3rd
|
2011
|
| Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients
|
Bonte, F. J., Weiner, M. F., Bigio, E. H., White, C. L., 3rd
|
1997
|
| Optimized classification of <sup>18</sup>F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment
|
Bullich, S., Seibyl, J., Catafau, A. M., Jovalekic, A., Koglin, N., Barthel, H., Sabri, O., De Santi, S.
|
2017
|
| Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis
|
Burton, E. J., Barber, R., Mukaetova-Ladinska, E. B., Robson, J., Perry, R. H., Jaros, E., Kalaria, R. N., O'Brien, J. T.
|
2009
|
| Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study.[Erratum appears in Lancet Neurol. 2012 Aug;11(8):658]
|
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., Schneider, J. A., Arora, A., Carpenter, A. P., Flitter, M. L., Joshi, A. D., Krautkramer, M. J., Lu, M., Mintun, M. A., Skovronsky, D. M., Group, Av- A. Study
|
2012
|
| Use of florbetapir-PET for imaging beta-amyloid pathology
|
Clark, C. M., Schneider, J. A., Bedell, B. J., Beach, T. G., Bilker, W. B., Mintun, M. A., Pontecorvo, M. J., Hefti, F., Carpenter, A. P., Flitter, M. L., Krautkramer, M. J., Kung, H. F., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Sabbagh, M. N., Sadowsky, C. H., Reiman, E. P., Zehntner, S. P., Skovronsky, D. M., Group, Av A. Study
|
2011
|
| Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
|
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Jr., Farlow, M., Weitlauf, S. L., Quinn, J., Kaye, J., Knopman, D., Arai, H., Doody, R. S., DeCarli, C., Leight, S., Lee, V. M., Trojanowski, J. Q.
|
2003
|
| Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density
|
Curtis, C., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., Walker, Z., Hunjan, A., Holmes, C., Escovar, Y. M., Vera, C. X., Agronin, M. E., Ross, J., Bozoki, A., Akinola, M., Shi, J., Vandenberghe, R., Ikonomovic, M. D., Sherwin, P. F., Grachev, I. D., Farrar, G., Smith, A. P., Buckley, C. J., McLain, R., Salloway, S.
|
2015
|
| Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia
|
Engelborghs, S., De Vreese, K., Van de Casteele, T., Vanderstichele, H., Van Everbroeck, B., Cras, P., Martin, J. J., Vanmechelen, E., De Deyn, P. P.
|
2008
|
| FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
|
Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Turner, R. S., Koeppe, R. A., Higdon, R., Minoshima, S.
|
2007
|
| MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases
|
Harper, L., Fumagalli, G. G., Barkhof, F., Scheltens, P., O'Brien, J. T., Bouwman, F., Burton, E. J., Rohrer, J. D., Fox, N. C., Ridgway, G. R., Schott, J. M.
|
2016
|
| Post-mortem histopathology underlying beta-amyloid PET imaging following flutemetamol F 18 injection
|
Ikonomovic, M. D., Buckley, C. J., Heurling, K., Sherwin, P., Jones, P. A., Zanette, M., Mathis, C. A., Klunk, W. E., Chakrabarty, A., Ironside, J., Ismail, A., Smith, C., Thal, D. R., Beach, T. G., Farrar, G., Smith, A. P.
|
2016
|
| Comparison of cerebrospinal fluid levels of tau and Abeta 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms
|
Irwin, D. J., McMillan, C. T., Toledo, J. B., Arnold, S. E., Shaw, L. M., Wang, L. S., Van Deerlin, V., Lee, V. M., Trojanowski, J. Q., Grossman, M.
|
2012
|
| What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
|
Jagust, W., Reed, B., Mungas, D., Ellis, W., Decarli, C.
|
2007
|
| SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study
|
Jagust, W., Thisted, R., Devous, M. D., Sr., Van Heertum, R., Mayberg, H., Jobst, K., Smith, A. D., Borys, N.
|
2001
|
| Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging.[Republished from Int Psychogeriatr. 1997;9 Suppl 1:191-222; discussion 247-52; PMID: 9447442]
|
Jobst, K. A., Barnetson, L. P., Shepstone, B. J.
|
1998
|
| A Semiautomated Method for Quantification of F 18 Florbetapir PET Images
|
Joshi, A. D., Pontecorvo, M. J., Lu, M., Skovronsky, D. M., Mintun, M. A., Devous, M. D., Sr.
|
2015
|
| Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P)
|
Koopman, K., Le Bastard, N., Martin, J. J., Nagels, G., De Deyn, P. P., Engelborghs, S.
|
2009
|
| Multisite study of the relationships between antemortem [<sup>11</sup>C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology
|
La Joie, R., Ayakta, N., Seeley, W. W., Borys, E., Boxer, A. L., DeCarli, C., Dore, V., Grinberg, L. T., Huang, E., Hwang, J. H., Ikonomovic, M. D., Jack, C., Jr., Jagust, W. J., Jin, L. W., Klunk, W. E., Kofler, J., Lesman-Segev, O. H., Lockhart, S. N., Lowe, V. J., Masters, C. L., Mathis, C. A., McLean, C. L., Miller, B. L., Mungas, D., O'Neil, J. P., Olichney, J. M., Parisi, J. E., Petersen, R. C., Rosen, H. J., Rowe, C. C., Spina, S., Vemuri, P., Villemagne, V. L., Murray, M. E., Rabinovici, G. D.
|
2019
|
| Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia
|
Le Bastard, N., Coart, E., Vanderstichele, H., Vanmechelen, E., Martin, J. J., Engelborghs, S.
|
2013
|
| Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease
|
Roher, A. E., Maarouf, C. L., Sue, L. I., Hu, Y., Wilson, J., Beach, T. G.
|
2009
|
| Contribution of single photon emission computed tomography to the differential diagnosis of dementia in a memory clinic
|
Rollin-Sillaire, A., Bombois, S., Deramecourt, V., Steinert-Emptaz, A., Salleron, J., Morvan, J., Maurage, C. A., Steinling, M., Pasquier, F.
|
2012
|
| The CT-based radial width of the temporal horn: pathological validation in AD without cerebrovascular disease
|
Rossi, R., Joachim, C., Smith, A. D., Frisoni, G. B.
|
2004
|
| Use of fuzzy edge single-photon emission computed tomography analysis in definite Alzheimer's disease--a retrospective study
|
Rusina, R., Kukal, J., Belicek, T., Buncova, M., Matej, R.
|
2010
|
| Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study
|
Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., Beach, T. G., Rowe, C. C., Leverenz, J. B., Ghetti, B., Ironside, J. W., Catafau, A. M., Stephens, A. W., Mueller, A., Koglin, N., Hoffmann, A., Roth, K., Reininger, C., Schulz-Schaeffer, W. J., Florbetaben Phase 3 Study, Group
|
2015
|
| Performance of [<sup>18</sup>F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
|
Salloway, S., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., Walker, Z., Hunjan, A., Escovar, Y. M., Agronin, M. E., Ross, J., Bozoki, A., Akinola, M., Shi, J., Vandenberghe, R., Ikonomovic, M. D., Sherwin, P. F., Farrar, G., Smith, A. P. L., Buckley, C. J., Thal, D. R., Zanette, M., Curtis, C.
|
2017
|
| Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort
|
Seeburger, J. L., Holder, D. J., Combrinck, M., Joachim, C., Laterza, O., Tanen, M., Dallob, A., Chappell, D., Snyder, K., Flynn, M., Simon, A., Modur, V., Potter, W. Z., Wilcock, G., Savage, M. J., Smith, A. D.
|
2015
|
| Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study
|
Seibyl, J., Catafau, A. M., Barthel, H., Ishii, K., Rowe, C. C., Leverenz, J. B., Ghetti, B., Ironside, J. W., Takao, M., Akatsu, H., Murayama, S., Bullich, S., Mueller, A., Koglin, N., Schulz-Schaeffer, W. J., Hoffmann, A., Sabbagh, M. N., Stephens, A. W., Sabri, O.
|
2016
|
| Regional correlations between [<sup>11</sup>C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort
|
Seo, S. W., Ayakta, N., Grinberg, L. T., Villeneuve, S., Lehmann, M., Reed, B., DeCarli, C., Miller, B. L., Rosen, H. J., Boxer, A. L., O'Neil, J. P., Jin, L. W., Seeley, W. W., Jagust, W. J., Rabinovici, G. D.
|
2017
|
| Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome
|
Silverman, D. H., Small, G. W., Chang, C. Y., Lu, C. S., Kung De Aburto, M. A., Chen, W., Czernin, J., Rapoport, S. I., Pietrini, P., Alexander, G. E., Schapiro, M. B., Jagust, W. J., Hoffman, J. M., Welsh-Bohmer, K. A., Alavi, A., Clark, C. M., Salmon, E., de Leon, M. J., Mielke, R., Cummings, J. L., Kowell, A. P., Gambhir, S. S., Hoh, C. K., Phelps, M. E.
|
2001
|
| Cerebrospinal fluid Abeta1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels
|
Slaets, S., Le Bastard, N., Martin, J. J., Sleegers, K., Van Broeckhoven, C., De Deyn, P. P., Engelborghs, S.
|
2013
|
| Amyloid pathology influences abeta1-42 cerebrospinal fluid levels in dementia with lewy bodies
|
Slaets, S., Le Bastard, N., Theuns, J., Sleegers, K., Verstraeten, A., De Leenheir, E., Luyckx, J., Martin, J. J., Van Broeckhoven, C., Engelborghs, S.
|
2013
|
| Increased CSF alpha-synuclein levels in Alzheimer's disease: correlation with tau levels
|
Slaets, S., Vanmechelen, E., Le Bastard, N., Decraemer, H., Vandijck, M., Martin, J. J., De Deyn, P. P., Engelborghs, S.
|
2014
|
| Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls
|
Struyfs, H., Molinuevo, J. L., Martin, J. J., De Deyn, P. P., Engelborghs, S.
|
2014
|
| Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain
|
Tapiola, T., Alafuzoff, I., Herukka, S. K., Parkkinen, L., Hartikainen, P., Soininen, H., Pirttila, T.
|
2009
|
| Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB
|
Thomas, A. J., Attems, J., Colloby, S. J., O'Brien, J. T., McKeith, I., Walker, R., Lee, L., Burn, D., Lett, D. J., Walker, Z.
|
2017
|
| Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads
|
Thurfjell, L., Lilja, J., Lundqvist, R., Buckley, C., Smith, A., Vandenberghe, R., Sherwin, P.
|
2014
|
| CSF biomarkers cutoffs: the importance of coincident neuropathological diseases
|
Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M., Shaw, L. M., Trojanowski, J. Q.
|
2012
|
| Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND
|
Vemuri, P., Simon, G., Kantarci, K., Whitwell, J. L., Senjem, M. L., Przybelski, S. A., Gunter, J. L., Josephs, K. A., Knopman, D. S., Boeve, B. F., Ferman, T. J., Dickson, D. W., Parisi, J. E., Petersen, R. C., Jack, C. R., Jr.
|
2011
|
| Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation
|
Villeneuve, S., Rabinovici, G. D., Cohn-Sheehy, B. I., Madison, C., Ayakta, N., Ghosh, P. M., La Joie, R., Arthur-Bentil, S. K., Vogel, J. W., Marks, S. M., Lehmann, M., Rosen, H. J., Reed, B., Olichney, J., Boxer, A. L., Miller, B. L., Borys, E., Jin, L. W., Huang, E. J., Grinberg, L. T., DeCarli, C., Seeley, W. W., Jagust, W.
|
2015
|
| Agitation in the demented elderly: a role for benzodiazepines?
|
Ancill, R. J.;Carlyle, W. W.;Liang, R. A.;Holliday, S. G.
|
1991
|
| Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease
|
Auchus, A. P.;Bissey-Black, C.
|
1997
|
| The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial
|
Ballard, C.;Hanney, M. L.;Theodoulou, M.;Douglas, S.;McShane, R.;Kossakowski, K.;Gill, R.;Juszczak, E.;Yu, L. M.;Jacoby, R.;Dart-Ad investigators
|
2009
|
| Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial
|
Ballard, C.;Margallo-Lana, M.;Juszczak, E.;Douglas, S.;Swann, A.;Thomas, A.;O'Brien, J.;Everratt, A.;Sadler, S.;Maddison, C.;Lee, L.;Bannister, C.;Elvish, R.;Jacoby, R.
|
2005
|
| A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD)
|
Ballard, C.;Thomas, A.;Gerry, S.;Yu, L. M.;Aarsland, D.;Merritt, C.;Corbett, A.;Davison, C.;Sharma, N.;Khan, Z.;Creese, B.;Loughlin, P.;Bannister, C.;Burns, A.;Win, S. N.;Walker, Z.;Main-Ad investigators
|
2015
|
| Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms
|
Ballard, C.;Youakim, J. M.;Coate, B.;Stankovic, S.
|
2019
|
| Buspirone vs. Haloperidol: A Double-Blind Trial for Agitation in a Nursing Home Population With Alzheimer's Disease
|
Cantillon, M.;Brunswick, R.;Molina, D.;Bahro, M.
|
1996
|
| Safety and effectiveness of donepezil on behavioral symptoms in patients with Alzheimer disease
|
Carrasco, M. M.;Aguera, L.;Gil, P.;Morinigo, A.;Leon, T.
|
2011
|
| A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients
|
Chan, W. C.;Lam, L. C.;Choy, C. N.;Leung, V. P.;Li, S. W.;Chiu, H. F.
|
2001
|
| Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study.[Erratum appears in J Clin Psychopharmacol. 2005 Dec;25(6):560 Note: Carson, William H [added]; Iwamoto, Taro [added]]
|
De Deyn, P.;Jeste, D. V.;Swanink, R.;Kostic, D.;Breder, C.;Carson, W. H.;Iwamoto, T.
|
2005
|
| Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease
|
De Deyn, P. P.;Carrasco, M. M.;Deberdt, W.;Jeandel, C.;Hay, D. P.;Feldman, P. D.;Young, C. A.;Lehman, D. L.;Breier, A.
|
2004
|
| Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study
|
De Deyn, P. P.;Eriksson, H.;Svensson, H.;Study, investigators
|
2012
|
| A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
|
De Deyn, P. P.;Rabheru, K.;Rasmussen, A.;Bocksberger, J. P.;Dautzenberg, P. L.;Eriksson, S.;Lawlor, B. A.
|
1999
|
| Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia
|
Deberdt, W. G.;Dysken, M. W.;Rappaport, S. A.;Feldman, P. D.;Young, C. A.;Hay, D. P.;Lehman, D. L.;Dossenbach, M.;Degenhardt, E. K.;Breier, A.
|
2005
|
| A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease
|
Devanand, D. P.;Marder, K.;Michaels, K. S.;Sackeim, H. A.;Bell, K.;Sullivan, M. A.;Cooper, T. B.;Pelton, G. H.;Mayeux, R.
|
1998
|
| A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil
|
Finkel, S. I.;Mintzer, J. E.;Dysken, M.;Krishnan, K. R.;Burt, T.;McRae, T.
|
2004
|
| A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities
|
Fontaine, C. S.;Hynan, L. S.;Koch, K.;Martin-Cook, K.;Svetlik, D.;Weiner, M. F.
|
2003
|
| Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial
|
Fox, C.;Crugel, M.;Maidment, I.;Auestad, B. H.;Coulton, S.;Treloar, A.;Ballard, C.;Boustani, M.;Katona, C.;Livingston, G.
|
2012
|
| Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial
|
Hall, K. A.;Keks, N. A.;O'Connor, D. W.
|
2005
|
| Mortality in elderly dementia patients treated with risperidone
|
Haupt, M.;Cruz-Jentoft, A.;Jeste, D.
|
2006
|
| A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease
|
Herrmann, N.;Gauthier, S.;Boneva, N.;Lemming, O. M.;Investigators
|
2013
|
| Atypical antipsychotics and risk of cerebrovascular accidents
|
Herrmann, N.;Mamdani, M.;Lanctot, K. L.
|
2004
|
| Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study
|
Holmes, C.;Wilkinson, D.;Dean, C.;Clare, C.;El-Okl, M.;Hensford, C.;Moghul, S.
|
2007
|
| Donepezil for the treatment of agitation in Alzheimer's disease
|
Howard, R. J.;Juszczak, E.;Ballard, C. G.;Bentham, P.;Brown, R. G.;Bullock, R.;Burns, A. S.;Holmes, C.;Jacoby, R.;Johnson, T.;Knapp, M.;Lindesay, J.;O'Brien, J. T.;Wilcock, G.;Katona, C.;Jones, R. W.;DeCesare, J.;Rodger, M.;Calm-Ad Trial Group
|
2007
|
| Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761 in Alzheimer's disease and vascular dementia: results from a randomised controlled trial
|
Ihl, R.;Tribanek, M.;Bachinskaya, N.;Gotaday Study Group
|
2012
|
| The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease
|
Kennedy, J. S.;Zagar, A.;Bymaster, F.;Nomikos, G.;Trzepacz, P. T.;Gilmore, J. A.;Rotelli, M. D.;Breier, A.;Tollefson, G.
|
2001
|
| Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice
|
Kurz, A.;Schwalen, S. S.;Schmitt, A.
|
2005
|
| Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: results from a short-term, randomized, double-blind trial
|
Kyomen, H. H.;Satlin, A.;Hennen, J.;Wei, J. Y.
|
1999
|
| Fluvoxamine for psychosis in Alzheimer's disease
|
Levkovitz, Y.;Bloch, Y.;Kaplan, D.;Diskin, A.;Abramovitchi, I.
|
2001
|
| Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses
|
Mintzer, J. E.;Tune, L. E.;Breder, C. D.;Swanink, R.;Marcus, R. N.;McQuade, R. D.;Forbes, A.
|
2007
|
| Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis
|
Mintzer, J.;Faison, W.;Street, J. S.;Sutton, V. K.;Breier, A.
|
2001
|
| Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial
|
Mintzer, J.;Greenspan, A.;Caers, I.;Van Hove, I.;Kushner, S.;Weiner, M.;Gharabawi, G.;Schneider, L. S.
|
2006
|
| Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer's Disease: Analysis of the CATIE-AD Study
|
Nagata, T.;Shinagawa, S.;Nakajima, S.;Mimura, M.;Shigeta, M.
|
2018
|
| Placebo Effects in the Treatment of Noncognitive Symptoms of Alzheimer's Disease: Analysis of the CATIE-AD Data
|
Ozawa, C.;Roberts, R.;Yoshida, K.;Suzuki, T.;Lebowitz, B.;Reeves, S.;Howard, R.;Abe, T.;Mimura, M.;Uchida, H.
|
2017
|
| Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function
|
Rainer, M.;Haushofer, M.;Pfolz, H.;Struhal, C.;Wick, W.
|
2007
|
| Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease
|
Schneider, L. S.;Tariot, P. N.;Dagerman, K. S.;Davis, S. M.;Hsiao, J. K.;Ismail, M. S.;Lebowitz, B. D.;Lyketsos, C. G.;Ryan, J. M.;Stroup, T. S.;Sultzer, D. L.;Weintraub, D.;Lieberman, J. A.;Catie-Ad Study Group
|
2006
|
| Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group
|
Street, J. S.;Clark, W. S.;Gannon, K. S.;Cummings, J. L.;Bymaster, F. P.;Tamura, R. N.;Mitan, S. J.;Kadam, D. L.;Sanger, T. M.;Feldman, P. D.;Tollefson, G. D.;Breier, A.
|
2000
|
| Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial
|
Tariot, P. N.;Raman, R.;Jakimovich, L.;Schneider, L.;Porsteinsson, A.;Thomas, R.;Mintzer, J.;Brenner, R.;Schafer, K.;Thal, L.;Alzheimer's Disease Cooperative, Study;Valproate Nursing Home Study, Group
|
2005
|
| Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.[Erratum appears in Am J Geriatr Psychiatry. 2006 Nov;14(11):988]
|
Tariot, P. N.;Schneider, L.;Katz, I. R.;Mintzer, J. E.;Street, J.;Copenhaver, M.;Williams-Hughes, C.
|
2006
|
| Treatment of agitation in AD: A randomized, placebo-controlled clinical trial
|
Teri, L.;Logsdon, R. G.;Peskind, E.;Raskind, M.;Weiner, M. F.;Tractenberg, R. E.;Foster, N. L.;Schneider, L. S.;Sano, M.;Whitehouse, P.;Tariot, P.;Mellow, A. M.;Auchus, A. P.;Grundman, M.;Thomas, R. G.;Schafer, K.;Thal, L. J.
|
2000
|
| Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial
|
Verhey, F. R.;Verkaaik, M.;Lousberg, R.;Olanzapine-Haloperidol in Dementia Study, group
|
2006
|
| Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia
|
Viscogliosi, G.;Chiriac, I. M.;Ettorre, E.
|
2017
|
| Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study
|
Zheng, L.;Mack, W. J.;Dagerman, K. S.;Hsiao, J. K.;Lebowitz, B. D.;Lyketsos, C. G.;Stroup, T. S.;Sultzer, D. L.;Tariot, P. N.;Vigen, C.;Schneider, L. S.
|
2009
|
| Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study
|
Zhong, K. X.;Tariot, P. N.;Mintzer, J.;Minkwitz, M. C.;Devine, N. A.
|
2007
|
| Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer's disease: A clinical trial
|
Zhou, T.;Wang, J.;Xin, C.;Kong, L.;Wang, C.
|
2019
|
| Trail Making Test errors in normal aging, mild cognitive impairment, and dementia
|
Ashendorf, L.;Jefferson, A. L.;O'Connor, M. K.;Chaisson, C.;Green, R. C.;Stern, R. A.
|
2008
|
| Utility of a modified version of the wisconsin card sorting test in the detection of dementia of the alzheimer type
|
Bondi, M. W.;Monsch, A. U.;Butters, N.;Salmon, D. P.;Paulsen, J. S.
|
1993
|
| Dual-retrieval models and neurocognitive impairment
|
Brainerd, C. J.;Reyna, V. F.;Gomes, C. F.;Kenney, A. E.;Gross, C. J.;Taub, E. S.;Spreng, R. N.;Alzheimer's Disease Neuroimaging, Initiative
|
2014
|
| Data from a longitudinal study provided measurements of cognition to screen for Alzheimer's disease
|
Brant, L. J.;Sheng, S. L.;Morrell, C. H.;Zonderman, A. B.
|
2005
|
| The Clock Drawing Test for dementia of the Alzheimer's type: A comparison of three scoring methods in a memory disorders clinic
|
Brodaty, H.;Moore, C. M.
|
1997
|
| Self administered cognitive screening test (TYM) for detection of Alzheimer's disease: cross sectional study
|
Brown, J.;Pengas, G.;Dawson, K.;Brown, L. A.;Clatworthy, P.
|
2009
|
| Screening for dementia with the memory impairment screen
|
Buschke, H.;Kuslansky, G.;Katz, M.;Stewart, W. F.;Sliwinski, M. J.;Eckholdt, H. M.;Lipton, R. B.
|
1999
|
| Detection of dementia of the Alzheimer type in a population-based sample: neuropsychological test performance
|
Cahn, D. A.;Salmon, D. P.;Butters, N.;Wiederholt, W. C.;Corey-Bloom, J.;Edelstein, S. L.;Barrett-Connor, E.
|
1995
|
| Screening for dementia of the alzheimer type in the community: the utility of the Clock Drawing Test
|
Cahn, D. A.;Salmon, D. P.;Monsch, A. U.;Butters, N.;Wiederholt, W. C.;Corey-Bloom, J.;Barrett-Connor, E.
|
1996
|
| A population-based analysis of qualitative features of the neuropsychological test performance of individuals with dementia of the Alzheimer type: implications for individuals with questionable dementia
|
Cahn, D. A.;Salmon, D. P.;Bondi, M. W.;Butters, N.;Johnson, S. A.;Wiederholt, W. C.;Barrett-Connor, E.
|
1997
|
| Diagnostic utility of abbreviated fluency measures in Alzheimer disease and vascular dementia
|
Canning, S. J.;Leach, L.;Stuss, D.;Ngo, L.;Black, S. E.
|
2004
|
| Diagnostic utility of letter fluency, category fluency, and fluency difference scores in Alzheimer's disease
|
Cerhan, J. H.;Ivnik, R. J.;Smith, G. E.;Tangalos, E. C.;Petersen, R. C.;Boeve, B. F.
|
2002
|
| A total score for the CERAD neuropsychological battery
|
Chandler, M. J.;Lacritz, L. H.;Hynan, L. S.;Barnard, H. D.;Allen, G.;Deschner, M.;Weiner, M. F.;Cullum, C. M.
|
2005
|
| Diagnosis of Alzheimer's disease using neuropsychological testing improved by multivariate analyses
|
Chapman, R. M.;Mapstone, M.;Porsteinsson, A. P.;Gardner, M. N.;McCrary, J. W.;DeGrush, E.;Reilly, L. A.;Sandoval, T. C.;Guillily, M. D.
|
2010
|
| Latent information in fluency lists predicts functional decline in persons at risk for Alzheimer disease
|
Clark, D. G.;Kapur, P.;Geldmacher, D. S.;Brockington, J. C.;Harrell, L.;DeRamus, T. P.;Blanton, P. D.;Lokken, K.;Nicholas, A. P.;Marson, D. C.
|
2014
|
| Diagnostic accuracy of percent retention scores on RBANS verbal memory subtests for the diagnosis of Alzheimer's disease and mild cognitive impairment
|
Clark, J. H.;Hobson, V. L.;O'Bryant, S. E.
|
2010
|
| Memory impairment in Alzheimer's disease: Replication and extension of the delayed world recall (DWR) test
|
Coen, R. F.;Swanwick, G. R. J.;Maguire, C.;Kirby, M.;Lawlor, B. A.;Walsh, J. B.;Coakley, D.
|
1996
|
| Performance of three clock scoring systems across different ranges of dementia severity
|
Connor, D. J.;Seward, J. D.;Bauer, J. A.;Golden, K. S.;Salmon, D. P.
|
2005
|
| Sensitivity and specificity of neuropsychological tests for mild cognitive impairment, vascular cognitive impairment and Alzheimer's disease
|
De Jager, C. A.;Hogervorst, E.;Combrinck, M.;Budge, M. M.
|
2003
|
| The Utility of the Addenbrooke's Cognitive Examination Version Three in Early-Onset Dementia
|
Elamin, M.;Holloway, G.;Bak, T. H.;Pal, S.
|
2016
|
| Clock drawing test in very mild Alzheimer's disease
|
Esteban-Santillan, C.;Praditsuwan, R.;Ueda, H.;Geldmacher, D. S.
|
1998
|
| Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance
|
Ewers, M.;Walsh, C.;Trojanowski, J. Q.;Shaw, L. M.;Petersen, R. C.;Jack, C. R.;Jr, Feldman;H. H, Bokde;A. L, Alexander;G. E, Scheltens;P, Vellas;B, Dubois;B, Weiner;M, Hampel;H, North American Alzheimer's Disease Neuroimaging
|
2012
|
| The Mini-Mental State Examination in the early diagnosis of Alzheimer's disease
|
Galasko, Douglas;Klauber, Melville R.;Hofstetter, C.;Salmon, David P.;Lasker, Bruce;Thal, Leon J.
|
1990
|
| Diagnostic utility of the NAB List Learning test in Alzheimer's disease and amnestic mild cognitive impairment
|
Gavett, B. E.;Poon, S. J.;Ozonoff, A.;Jefferson, A. L.;Nair, A. K.;Green, R. C.;Stern, R. A.
|
2009
|
| Using verbal fluency to detect very mild dementia of the Alzheimer type
|
Gomez, R. G.;White, D. A.
|
2006
|
| Neuropsychological strategies for detecting early dementia
|
Grober, E.;Hall, C.;McGinn, M.;Nicholls, T.;Stanford, S.;Ehrlich, A.;Jacobs, L. G.;Kennedy, G.;Sanders, A.;Lipton, R. B.
|
2008
|
| Free and cued selective reminding distinguishes Alzheimer's disease from vascular dementia
|
Grober, E.;Hall, C.;Sanders, A. E.;Lipton, R. B.
|
2008
|
| Utility of the NIH Toolbox for assessment of prodromal Alzheimer's disease and dementia
|
Hackett, K.;Krikorian, R.;Giovannetti, T.;Melendez-Cabrero, J.;Rahman, A.;Caesar, E. E.;Chen, J. L.;Hristov, H.;Seifan, A.;Mosconi, L.;Isaacson, R. S.
|
2018
|
| The Brief Memory and Executive Test (BMET): A cognitive screening tool to detect and differentiate vascular cognitive impairment and Alzheimer's disease
|
Hollocks, M. J.;Brookes, R. L.;Morris, R. G.;Markus, H. S.
|
2018
|
| Discourse analysis of logical memory recall in normal aging and in dementia of the Alzheimer type
|
Johnson, D. K.;Storandt, M.;Balota, D. A.
|
2003
|
| DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia
|
Kalbe, E.;Kessler, J.;Calabrese, P.;Smith, R.;Passmore, A. P.;Brand, M.;Bullock, R.
|
2004
|
| A verbal memory test with high predictive accuracy for dementia of the Alzheimer type
|
Knopman, D. S.;Ryberg, S.
|
1989
|
| Screening for Alzheimer's disease: the memory impairment screen versus the conventional three-word memory test
|
Kuslansky, G.;Buschke, H.;Katz, M.;Sliwinski, M.;Lipton, R. B.
|
2002
|
| Detecting dementia with the Hopkins Verbal Learning Test and the Mini-Mental State Examination
|
Kuslansky, G.;Katz, M.;Verghese, J.;Hall, C. B.;Lapuerta, P.;LaRuffa, G.;Lipton, R. B.
|
2004
|
| Application of new WAIS-III/WMS-III discrepancy scores for evaluating memory functioning: relationship between intellectual and memory ability
|
Lange, R. T.;Chelune, G. J.
|
2006
|
| Use of the clock drawing task in the diagnosis of mild and very mild Alzheimer's disease
|
Lee, H.;Swanwick, G. R.;Coen, R. F.;Lawlor, B. A.
|
1996
|
| The utility of a modified object memory test in distinguishing between different age groups of Alzheimer's disease patients and normal controls
|
Loewenstein, D. A.;Arguelles, T.;Acevedo, A.;Freeman, R. Q.;Mendelssohn, E.;Ownby, R. L.;White, G.;Mogosky, B. J.;Schram, L.;Barker, W.;Rodriguez, I.;Duara, R.
|
2001
|
| The WAIS-R profile: A diagnostic tool for Alzheimer's disease?
|
Logsdon, R. G.;Teri, L.;Williams, D. E.;Vitiello, M. V.;Prinz, P. N.
|
1989
|
| The TE4D-Cog: a new test for detecting early dementia in English-speaking populations
|
Mahoney, R.;Johnston, K.;Katona, C.;Maxmin, K.;Livingston, G.
|
2005
|
| Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease
|
Maruff, P.;Lim, Y. Y.;Darby, D.;Ellis, K. A.;Pietrzak, R. H.;Snyder, P. J.;Bush, A. I.;Szoeke, C.;Schembri, A.;Ames, D.;Masters, C. L.
|
2013
|
| A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia
|
Mathuranath, P. S.;Nestor, P. J.;Berrios, G. E.;Rakowicz, W.;Hodges, J. R.
|
2000
|
| Development of scoring criteria for the clock drawing task in Alzheimer's disease
|
Mendez, M. F.;Ala, T.;Underwood, K. L.
|
1992
|
| Designing a Brief Alzheimer Screen (BAS)
|
Mendiondo, M. S.;Ashford, J. W.;Kryscio, R. J.;Schmitt, F. A.
|
2003
|
| Process dissociation analyses of memory changes in healthy aging, preclinical, and very mild Alzheimer disease: Evidence for isolated recollection deficits
|
Millar, P. R.;Balota, D. A.;Maddox, G. B.;Duchek, J. M.;Aschenbrenner, A. J.;Fagan, A. M.;Benzinger, T. L. S.;Morris, J. C.
|
2017
|
| Comparisons of verbal fluency tasks in the detection of dementia of the Alzheimer type
|
Monsch, A. U.;Bondi, M. W.;Butters, N.;Salmon, D. P.;Katzman, R.;Thal, L. J.
|
1992
|
| Clinical validity of the Mattis Dementia Rating Scale in detecting Dementia of the Alzheimer type. A double cross-validation and application to a community-dwelling sample
|
Monsch, A. U.;Bondi, M. W.;Salmon, D. P.;Butters, N.;Thal, L. J.;Hansen, L. A.;Wiederholt, W. C.;Cahn, D. A.;Klauber, M. R.
|
1995
|
| Effects of Delay Duration on the WMS Logical Memory Performance of Older Adults with Probable Alzheimer's Disease, Probable Vascular Dementia, and Normal Cognition
|
Montgomery, V.;Harris, K.;Stabler, A.;Lu, L. H.
|
2017
|
| Assessment of the RBANS Visual and Verbal Indices in a sample of neurologically impaired elderly participants
|
Morgan, D. R.;Linck, J.;Scott, J.;Adams, R.;Mold, J.
|
2010
|
| Quantitative and qualitative analyses of the clock drawing test in mild cognitive impairment and Alzheimer disease: evaluation of a modified scoring system
|
Parsey, C. M.;Schmitter-Edgecombe, M.
|
2011
|
| Memory function in very early Alzheimer's disease
|
Petersen, R. C.;Smith, G. E.;Ivnik, R. J.;Kokmen, E.;Tangalos, E. G.
|
1994
|
| Odor Identification Screening Improves Diagnostic Classification in Incipient Alzheimer's Disease
|
Quarmley, M.;Moberg, P. J.;Mechanic-Hamilton, D.;Kabadi, S.;Arnold, S. E.;Wolk, D. A.;Roalf, D. R.
|
2017
|
| Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging
|
Roalf, D. R.;Moberg, P. J.;Xie, S. X.;Wolk, D. A.;Moelter, S. T.;Arnold, S. E.
|
2013
|
| Bridging cognitive screening tests in neurologic disorders: A crosswalk between the short Montreal Cognitive Assessment and Mini-Mental State Examination
|
Roalf, D. R.;Moore, T. M.;Mechanic-Hamilton, D.;Wolk, D. A.;Arnold, S. E.;Weintraub, D. A.;Moberg, P. J.
|
2017
|
| Alzheimer's disease can be accurately diagnosed in very mildly impaired individuals
|
Salmon, D. P.;Thomas, R. G.;Pay, M. M.;Booth, A.;Hofstetter, C. R.;Thal, L. J.;Katzman, R.
|
2002
|
| A 7 minute neurocognitive screening battery highly sensitive to Alzheimer's disease
|
Solomon, P. R.;Hirschoff, A.;Kelly, B.;Relin, M.;Brush, M.;DeVeaux, R. D.;Pendlebury, W. W.
|
1998
|
| Recognition of Alzheimer's disease: the 7 Minute Screen
|
Solomon, P. R.;Pendlebury, W. W.
|
1998
|
| Screening for Mild Cognitive Impairment Using the Dementia Rating Scale-2
|
Springate, B. A.;Tremont, G.;Papandonatos, G.;Ott, B. R.
|
2014
|
| Very mild senile dementia of the Alzheimer type: II. Psychometric test performance
|
Storandt, Martha;Hill, Robert D.
|
1989
|
| Untimed Design Fluency in Aging and Alzheimer's Disease: Psychometrics and Normative Data
|
Sunderaraman, P.;Sokolov, E.;Cines, S.;Sullo, E.;Orly, A.;Lerer, B.;Karlawish, J.;Huey, E.;Cosentino, S.
|
2015
|
| Sensitivity and test-retest reliability of the international shopping list test in assessing verbal learning and memory in mild alzheimer's disease
|
Thompson, T. A. C.;Wilson, P. H.;Snyder, P. J.;Pietrzak, R. H.;Darby, D.;Maruff, P.;Buschke, H.
|
2011
|
| Use of the telephone-administered Minnesota Cognitive Acuity Screen to detect mild cognitive impairment
|
Tremont, G.;Papandonatos, G. D.;Springate, B.;Huminski, B.;McQuiggan, M. D.;Grace, J.;Frakey, L.;Ott, B. R.
|
2011
|
| The diagnostic utility of savings scores: differentiating Alzheimer's and Huntington's diseases with the logical memory and visual reproduction tests
|
Troster, A. I.;Butters, N.;Salmon, D. P.;Cullum, C. M.;Jacobs, D.;Brandt, J.;White, R. F.
|
1993
|
| Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults
|
Trzepacz, P. T.;Hochstetler, H.;Wang, S.;Walker, B.;Saykin, A. J.
|
2015
|
| The Clock Test: a sensitive measure to differentiate normal elderly from those with Alzheimer disease
|
Tuokko, H.;Hadjistavropoulos, T.;Miller, J. A.;Beattie, B. L.
|
1992
|
| Effect of education on the mini-mental state examination as a screening test for dementia
|
Uhlmann, R. F.;Larson, E. B.
|
1991
|
| Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease
|
Welsh, K. A.;Butters, N.;Hughes, J. P.;Mohs, R. C.;Heyman, A.
|
1992
|
| Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures
|
Welsh, K.;Butters, N.;Hughes, J.;Mohs, R.;Heyman, A.
|
1991
|
| Screening for Alzheimer's disease by clock drawing
|
Wolf-Klein, G. P.;Silverstone, F. A.;Levy, A. P.;Brod, M. S.
|
1989
|
| Psychometric Properties of Alzheimer's Disease Assessment Scale-Cognitive Subscale for Mild Cognitive Impairment and Mild Alzheimer's Disease Patients in an Asian Context
|
Zainal, N. H.;Silva, E.;Lim, L. L.;Kandiah, N.
|
2016
|